Dabur misses estimates, profit drops 8% to Rs 320 crore

Dabur India on Wednesday reported an 8.4% year-on-year decline in net profit for the January–March quarter, at Rs 320.13 crore. The figure fell short of Bloomberg’s consensus estimate of Rs 324 crore, as tepid urban demand, particularly in general trade channels, continued to weigh on performance.

Revenue from operations for the quarter rose a marginal 0.6% year-on-year to Rs 2,830.14 crore, below Bloomberg’s projection of Rs 2,846 crore. The company’s Ebitda also missed expectations, registering at Rs 426.8 crore against a projected Rs 438 crore.

Dabur’s underperformance in urban general trade was a key drag, despite double-digit growth across modern trade, e-commerce, and rural channels. CEO Mohit Malhotra acknowledged the pressure in urban consumption and laid out a refreshed seven-point strategic plan aimed at delivering a double-digit compound annual growth rate (CAGR) by FY28.

Central to this plan is a sharpened focus on Dabur’s core portfolio, which includes brands like Dabur Red, Real, Chyawanprash, Honey, Hajmola, Odonil, and Vatika, accounting for roughly 70% of total business. The company intends to step up investments in these high-conviction brands to gain market share, while also pruning underperforming categories such as vedic teas and diapers to reallocate capital more efficiently.

In addition, Dabur plans to drive premiumisation across its portfolio to bolster margins. It has identified growth segments such as hair serums, conditioners, and health gummies, and is preparing to launch zero-sugar, preservative-free beverages as part of this strategy. Malhotra said this move aligns with shifting consumer preferences and will help Dabur pivot toward higher-value offerings.

To further address urban trade inefficiencies, Dabur aims to consolidate its network of stockists to optimise return on investment and reduce cost-to-serve in metro markets. It also plans to strengthen its presence in high-growth channels, including e-commerce, quick commerce, and modern trade, which have shown sustained momentum.

Dabur India plunges 7.5%: 3 big concerns for investors

The company is also eyeing inorganic growth through mergers and acquisitions in segments like new-age healthcare, wellness foods, and premium personal care. Malhotra described this approach as part of building a future-fit portfolio that aligns with evolving consumer demands.

Looking ahead, Dabur expects sequential recovery from the April–June quarter and is targeting high single-digit to low double-digit revenue growth in FY26. For the full year FY25, net profit declined to Rs 1,740.42 crore from Rs 1,811.31 crore in FY24. The board has recommended a final dividend of Rs 5.25 per equity share for the fiscal.

Related Posts

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Bengaluru: In a major breakthrough in the illegal pharmaceutical network operating in Karnataka, investigators from the Special Investigation Team (SIT) raided Krupa Health Care at Minerva Circle, seizing a cache…

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Lundbeck, a biopharmaceutical company focusing exclusively on brain health, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909), Lundbeck’s novel…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

Spurious drug probe: SIT raids medical store in Bengaluru, detains proprietor

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

US FDA grants orphan drug designation for Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart to treat endogenous Cushing’s syndrome

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Fujifilm India installs Echelon Smart MRI at Jansons Health in Erode

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Rajasthan to prepare ‘Narcotics Control Vision 2026-29’ to curb drug abuse and trafficking

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

Bracco Imaging expands BubbleGen cell selection with CD3+ T Cell Isolation Kit

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched

5 medicine samples found substandard in Bhiwadi warehouse raid; probe launched